arGEN-X, Shire strike therapeutic antibody alliance
Under the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments, and in return for its option to develop and commercialize products,
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The company has gained an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The